Antimicrobial Resistance in Campylobacter

Project Code: 6.41
Completed: July 2012

Project Title:

Development of a Longitudinal Antimicrobial Resistance and Antimicrobial Use Surveillance Program for the Feedlot Sector in Western Canada

Researchers:

G. Douglas Inglis Douglas.Inglis@AGR.GC.CA

L. Brent Selinger

Background: Campylobacter bacteria can cause intestinal cramping, abdominal pain, fever, nausea, headaches and bloody diarrhea, especially in very young people or those with weak immune systems. Some infected people show no symptoms at all. Electrolytes and fluids are the most commonly prescribed treatment, although antibiotics may be prescribed in severe cases.

Southern Alberta has the highest rates of human campylobacteriosis and the largest cattle population in Canada, leading some people to blame cattle for human illness. Campylobacter jejuni does not typically cause illness in cattle, so these bacteria are not deliberately targeted when cattle are treated. However, Campylobacter can rapidly develop resistance to some antibiotics. Fluoroquinolone drugs like ciprofloxacin are of very high importance in human medicine. Although rarely used in beef cattle, Baytril (a fluoroquinolone) is approved to treat bovine respiratory disease. It is important to assess whether routine feedlot health management practices may contribute to human health risks in cattle producing areas.

Objectives

  1. Determine how antimicrobial resistance in C. jejuni changes over time in feedlot cattle,
  2. genetically compare C. jejuni found in beef cattle and humans living in southern Alberta, and
  3. determine which genetic factors contribute to fluoroquinolone resistance in C. jejuni.

What they did C. jejuni was isolated from individual fecal samples collected from 4,427 cattle at four commercial feedlots in Southern Alberta. Samples were collected on arrival, with a second sample collected after 60 days on feed. C. jejuni was also isolated from stools of human patients with enteritis in Southern Alberta. Isolates were DNA-fingerprinted to see if the C. jejuni found in cattle were the same as those found in humans. Antimicrobial resistance was also evaluated in C. jejuni isolated from the cattle and humans. Mutations in C. jejuni’s gyrA gene are involved in ciprofloxacin resistance, so ciprofloxacin resistant C. jejuni from cattle and humans were DNA sequenced to determine if they carried the same gyrA mutations.

What they learned Prevalence: C. jejuni was found in 27% of the cattle samples at arrival, and 61% after 60 days on feed. Of the 290 people in the Chinook Health Region diagnosed with enteritis over a one-year period; less than 11% were infected with C. jejuni.

C. jejuni in cattle and humans: Of the 592 genetically distinct types of C. jejuni found, 306 types were found in cattle, and 286 types were found in human patients. Only 54 genetic types were found in both cattle and humans, but these overlapping genetic types were very common. The overlapping genetic types accounted for 69% of the C. jejuni isolated from cattle and 43% of those from human patients.

Antimicrobial resistance to ciprofloxacin increased slightly (from 5.8 to 8.8%) between feedlot entry and 60 days on feed in cattle. The reason for this is unclear. Only 11 animals in one feedlot were treated with Baytril, and ciprofloxacin resistant C. jejuni was only isolated from one of these animals. The degree of ciprofloxacin resistant C. jejuni in cattle in this study was also higher than the 2.4% reported from fecal samples collected from healthy cattle entering abattoirs in the ongoing Public Health Agency of Canada’s Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) study.

Antimicrobial resistance was higher in C. jejuni from human patients than in C. jejuni from cattle samples for five of the seven antimicrobials tested in this study, and six out of seven tested in the CIPARS study.

Genetics of resistance differed between antimicrobial resistant C. jejuni from cattle and humans. The specific mutations in the gyrA gene found in antimicrobial resistant C. jejuni from cattle were very rarely found in antimicrobial resistant C. jejuni from humans (and vice versa). Three mutations accounted for over 75% of the ciprofloxacin resistant C. jejuni isolates from cattle, but these three mutations were found in less than 3% of the human isolates. Similarly, seven mutations accounted for over 75% of the ciprofloxacin resistant C. jejuni isolates from humans, but these seven mutations were found in less than 20% of the cattle isolates.

What it means: Cattle may not be the primary reservoir of C. jejuni (including antimicrobial resistant C. jejuni) responsible for the high rates of campylobacteriosis in Southern Alberta. Together with Alberta Health Service, these researchers are using more complex DNA techniques to identify important reservoirs of human infectious C. jejuni and transmission mechanisms.

View Fact Sheet PDF

Proudly Funded By:

© 2018 BCRC. All Rights Reserved | Privacy Policy | Terms of Service | Sitemap | info [at] beefresearch [dot] ca | Site By Media Dog
Facebook Twitter Youtube